Skip to main content

2019 News Releases

2019 News Releases

CSL Continues to Advance R&D Capabilities
04 Dec 2019

Unique portfolio mix of plasma, cell and gene therapy, recombinant proteins and antibody assets highlighted at Research & Development Briefing

Sydney, Australia

Harvard Business Review Names Paul Perreault Among Best Performing CEOs in the World
24 Oct 2019

King of Prussia, Pa.

Top 100 CEO rankings based on financial performance as well as environmental, social, and governance (ESG) ratings

CSL Behring Continues to Deliver on its Promise to Alpha1 Patients at the 29th Annual European Respiratory Society Congress
27 Sep 2019

• Focuses on Patients Through Disease Awareness Support Activities
• Hosts Patient-Focused Symposium on Alpha 1 Management

CSL Behring Delivers on its Promise to Advance Bleeding Disorder Treatment Research by Supporting 16 Data Presentations at ISTH 2019
01 Jul 2019

Melbourne, Australia

- Novel real world evidence for AFSTYLA® [Antihemophilic Factor (Recombinant), Single Chain] and IDELVION® ® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein] to be highlighted

CSL Behring to showcase clinical advances and insights in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with Hizentra ® [human normal immunoglobulin, 20%, subcutaneous], at the 2019 Peripheral Nerve Society Annual Meeting
20 Jun 2019

Genoa, Italy

- Eight posters including one oral presentation support ongoing research and clinical experience with Hizentra®, the first and only subcutaneous immunoglobulin (Ig) therapy approved to address the unique needs of CIDP patients.

- Presentations include new analysis from the PATH (Polyneuropathy and Treatment with Hizentra) study, the largest clinical trial in CIDP.

Top Coagulation Researchers Awarded Grants to Support Advancements in the Care of Patients with Bleeding Disorders
16 May 2019

Recipients from the US and Netherlands will be recognized in Marburg, Germany on Friday, 24 May

CSL Names Paul McKenzie as Chief Operating Officer
15 May 2019

Dr. McKenzie will be accountable for leading CSL’s global end-to-end supply chain organization and its accompanying strategy.

Global Biotherapeutics Leader CSL Behring Opens Regional Headquarters at Dubai Science Park
09 Apr 2019

Leading global biotech company brings innovative therapies for life-threatening medical conditions to UAE

Japan’s Ministry of Health, Labour and Welfare Approves CSL Behring Immunoglobulins to Treat Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
26 Mar 2019

CSL Behring announced today that Japan’s Ministry of Health, Labour and Welfare has approved two of its immunoglobulin therapies for the treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): Hizentra® and Privigen®

CSL Behring Extends Support of World Federation of Hemophilia Programs
04 Feb 2019

Reinforces Commitment to Providing Global Bleeding Disorders Community with Access to Care and Efforts to Increase Awareness

CSL Named One of the Best Employers in the US for Diversity
16 Jan 2019

Forbes Recognizes the Global Biotechnology Leader in its Top 50 Best Employers for Diversity 2019

Global Biotech Leader CSL to Present at J.P. Morgan Healthcare Conference on Wednesday, January 9
07 Jan 2019

CSL announced that it will present at the 2019 J.P. Morgan Annual Healthcare Conference.